ANTIVIRAL THERAPY
Scope & Guideline
Shaping the future of viral disease treatment.
Introduction
Aims and Scopes
- Antiviral Drug Development:
Research on new antiviral agents, including their mechanisms of action, efficacy, and safety profiles. - Clinical Trials and Observational Studies:
Investigation of antiviral therapies through controlled trials, real-world studies, and retrospective analyses to assess treatment outcomes. - Resistance Mechanisms:
Studies focused on understanding viral resistance to antiviral medications, including genotypic and phenotypic analyses. - Co-infection Studies:
Exploration of the interactions and treatment implications of co-infections, particularly between HIV, hepatitis viruses, and other pathogens. - Public Health and Epidemiology:
Research addressing the epidemiology of viral infections and the impact of antiviral therapies on public health outcomes. - Innovative Therapeutic Approaches:
Development and assessment of novel treatment strategies, including combination therapies, long-acting formulations, and personalized medicine.
Trending and Emerging
- COVID-19 and Post-Acute Sequelae:
An increasing number of studies are addressing the impact of COVID-19, including treatment approaches and the long-term effects of the virus on various populations. - Monoclonal Antibody Therapies:
Research focusing on the use of monoclonal antibodies in treating viral infections, particularly COVID-19 and other emerging viruses, is gaining traction. - HIV Treatment Innovations:
There is a growing focus on novel treatment regimens, including long-acting injectables and dual therapy approaches, reflecting ongoing advancements in HIV care. - Mechanistic Studies of Viral Pathogenesis:
Studies elucidating the mechanisms by which viruses evade immune responses and develop resistance are increasingly prominent, particularly in relation to emerging viruses. - Integrated Care Models for Co-infections:
Research on integrated care approaches for managing co-infections, particularly among vulnerable populations, is becoming more common as co-morbidities are recognized as critical factors in treatment.
Declining or Waning
- Traditional Antiviral Agents:
Research on older antiviral agents, such as acyclovir or older nucleoside analogs, has decreased as newer therapies and mechanisms gain prominence. - Vaccine Development:
While still relevant, the volume of publications specifically focused on vaccine development against viral infections has waned compared to other therapeutic strategies. - HIV/AIDS Related Stigma Studies:
Research examining the social stigma related to HIV/AIDS treatment and care has become less frequent, possibly due to a broader focus on clinical outcomes and therapy effectiveness. - Longitudinal Studies in Stable Populations:
Long-term studies examining stable populations with established treatment regimens have decreased, as the focus shifts to dynamic clinical settings and emerging therapies.
Similar Journals
Journal of Clinical Virology Plus
Transforming clinical virology through open-access research.The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.
VIROLOGICA SINICA
Advancing the Frontiers of Virology ResearchVIROLOGICA SINICA, published by KEAI PUBLISHING LTD, is a leading international journal dedicated to the field of virology. With an ISSN of 1674-0769 and E-ISSN of 1995-820X, this esteemed journal showcases cutting-edge research from 2006 to 2024, focusing on critical developments in Immunology, Infectious Diseases, Molecular Medicine, and Virology. As evidenced by its respectable positioning in the Q2 quartile of relevant categories and impressive Scopus rankings—such as Rank #20/80 in Virology—VIROLOGICA SINICA serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of viral pathogens and their impact on human health. While the journal does not currently offer open access, it remains an invaluable publication for those seeking to stay at the forefront of virology research. Its address is located at 16 Donghuangchenggen North St, Beijing, China, where it continues to foster academic excellence in the rapidly evolving landscape of virology.
INTERVIROLOGY
Uncovering breakthroughs in virology and infectious diseases.INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.
Hepatitis Monthly
Transforming insights into impactful clinical practices.Hepatitis Monthly, published by BRIEFLAND in the Netherlands, is a pivotal journal in the fields of hepatology and infectious diseases. Established in 2007, it continues to make significant contributions to the understanding and management of hepatitis and related viral infections with a publication timeline extending through to 2024. Aiming to disseminate high-quality research, the journal serves as a forum for groundbreaking studies and innovations essential for healthcare professionals, researchers, and students alike. While it currently holds Q4 rankings in both hepatology and infectious disease categories, its ongoing commitment to addressing pressing health issues makes it an important resource in the academic community. Although it operates under a traditional access model, Hepatitis Monthly not only publishes original research articles, reviews, and case studies but also encourages the exchange of knowledge that helps shape future research directions and clinical practices. As it continues to explore the complexities surrounding viral hepatitis, this journal invites researchers to contribute to its mission of advancing scientific understanding and improving patient care.
Microbiology Spectrum
Connecting researchers to the spectrum of microbial knowledge.Microbiology Spectrum is a prominent peer-reviewed journal published by the American Society for Microbiology, dedicated to advancing the field of microbiology through the dissemination of high-quality research. Since its inception in 2013 and continuing until 2024, the journal has established a strong presence in key domains such as microbiology, immunology, cell biology, and ecology, achieving impressive quartile rankings including Q1 in Infectious Diseases and Q1 in Immunology and Microbiology as of 2023. With an emphasis on open access to its scholarly content, Microbiology Spectrum aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike. The journal's scope encompasses a diverse range of topics pertinent to the field, making it an essential resource for anyone involved in microbiological research and its applications. Researchers looking to publish their findings in a respected journal will find Microbiology Spectrum's robust impact factor and Scopus rankings serve as testament to its significance and influence within the academic community.
JOURNAL OF CLINICAL VIROLOGY
Unveiling Breakthroughs in Clinical VirologyJournal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.
INVESTIGATIONAL NEW DRUGS
Elevating Therapeutic Strategies Through Rigorous ResearchINVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.
JOURNAL OF VIRAL HEPATITIS
Leading the charge in hepatitis research and innovation.The JOURNAL OF VIRAL HEPATITIS, published by WILEY, is a leading international journal dedicated to the dissemination of cutting-edge research in the fields of hepatology, infectious diseases, and virology. Established in 1994, this esteemed journal has created a significant impact within the scientific community, reflected by its ranking in the Q1 category for infectious diseases and Q2 for both hepatology and virology in the most recent quartile rankings. The journal provides an essential platform for scholars and practitioners to share their findings on viral hepatitis, enhancing our understanding of its pathogenesis, epidemiology, and treatment options. With its impact factor reflecting a robust citation record, the JOURNAL OF VIRAL HEPATITIS remains indispensable for those engaged in research and clinical practice regarding viral hepatitic infections. Researchers can access the journal through traditional subscription routes, underlining its commitment to advancing knowledge and fostering collaboration among scientists worldwide. As it approaches its convergence with new findings and innovative methodologies by 2024, the journal looks forward to continuing its pivotal role in shaping the future of hepatology research.
INFECTION
Exploring Innovations in Infection MedicineINFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.
Annual Review of Virology
Your essential resource for cutting-edge virology reviews.Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.